Search

Your search keyword '"Solit, David B"' showing total 2,030 results

Search Constraints

Start Over You searched for: Author "Solit, David B" Remove constraint Author: "Solit, David B"
2,030 results on '"Solit, David B"'

Search Results

1. Automated real-world data integration improves cancer outcome prediction

2. Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy

4. Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors

5. Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non-Muscle-Invasive Bladder Cancer

6. Differential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell/Neuroendocrine Carcinoma With Prognostic Implications

7. Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade

9. Treatment Patterns and Clinical Outcomes Among Patients With Metastatic Prostate Cancer Harboring Homologous Recombination Repair Mutations

10. Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer

11. The context-specific role of germline pathogenicity in tumorigenesis

12. Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy

13. Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial

14. Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma

15. Clonal evolution during metastatic spread in high-risk neuroblastoma

16. Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers

18. Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial

19. Genomic mapping of metastatic organotropism in lung adenocarcinoma

20. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

21. Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer

22. Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma

23. Genomic heterogeneity as a barrier to precision oncology in urothelial cancer

24. Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy

25. Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Advanced Hepatocellular Carcinoma

27. Anatomic position determines oncogenic specificity in melanoma

28. Clinicogenomic predictors of outcomes in patients with hepatocellular carcinoma treated with immunotherapy.

29. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

30. Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets

31. AKT mutant allele-specific activation dictates pharmacologic sensitivities

32. Author Correction: FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation

33. FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation

34. Utility of circulating tumor DNA (ctDNA) from cerebrospinal fluid (CSF) for prognosis of patients with recurrent high grade glioma.

35. Efficacy and genomic analysis of HER2-mutant, metastatic triple-negative breast cancer treated with neratinib alone or in combination with trastuzumab in the phase 2 SUMMIT basket trial.

36. Tracking the FDA precision oncology drug approval landscape in OncoKB.

38. PD14-07 ERCC2 ALTERATIONS ARE ASSOCIATED WITH ENHANCED SENSITIVITY TO INTRAVESICAL BACILLUS CALMETTE-GUÉRIN IN HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER

39. Molecular classification and diagnostics of upper urinary tract urothelial carcinoma

42. STING‐ATF3/type I interferon crosstalk: A potential target to improve anti‐tumour immunity in chemotherapy‐treated urothelial carcinoma.

43. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma

46. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial

47. GENOMIC CHARACTERIZATION OF HIGH-GRADE TA UROTHELIAL CARCINOMA WITH AND WITHOUT CARCINOMA IN SITU

48. DEVELOPMENT OF A GENOMIC PREDICTION MODEL FOR UPPER TRACT UROTHELIAL CARCINOMA STAGE

49. CARCINOMA IN SITU AND URINARY CYTOLOGY AS AN INDICATOR OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER TREATED WITH BCG

50. Homologous recombination deficiency and tumor suppressor heterozygosity mediate resistance to front-line therapy in breast cancer

Catalog

Books, media, physical & digital resources